Butyramide

Butyramide

SCHEMBL725174

CCCC(N)=O.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Butyramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyramide SCHEMBL29624901 1.00
Butyramide SCHEMBL2402186 1.00
Butyramide SCHEMBL9547386 0.97
Butyramide SCHEMBL27348828 0.97
Butyramide SCHEMBL27453923 0.97
Butyramide SCHEMBL9026624 0.97
Butyramide SCHEMBL5681 0.97
Butyramide SCHEMBL29664015 0.97
Butyramide SCHEMBL27345575 0.97 CES2 (0.53)
Butyramide SCHEMBL8555402 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605345-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2026-04-21 US claimed
US-20250268841-A1 Trans-Epithelial Membrane Drug Delivery System Masiz, John J. (US) 2025-08-28 US claimed
US-20250120907-A1 Transmucosal Drug Delivery System Masiz, John J. (US) 2025-04-17 US claimed
US-12246098-B2 Trans-epithelial membrane drug delivery system BioPhysics Pharma, Inc. (US) 2025-03-11 US claimed
US-20240425517-A1 NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION PRAZER THERAPEUTICS INC. (KR) 2024-12-26 US claimed
US-20240216292-A1 Trans-Epithelial Membrane Drug Delivery System Masiz, John J. (US) 2024-07-04 US claimed
US-20240108588-A1 Transdermal Drug Delivery System Masiz, John J. (US) 2024-04-04 US claimed
US-11865217-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2024-01-09 US claimed
EP-4106816-A1 TRANSMUCOSAL DRUG DELIVERY SYSTEM North Atlantic Holdings LLC (US) 2022-12-28 EP claimed
CN-115521328-A Organic boron fluorescent material and preparation method and application thereof 河南农业大学 2022-12-27 CN claimed
WO-2008156758-A1 BIFUNCTIONAL SYNTHETIC MOLECULES BIOCHEMICS, INC. (US) 2008-12-24 WO claimed
US-20080312296-A1 Bifunctional synthetic molecules ADEC PRIVATE EQUITY INVESTMENTS, LLC 2008-12-18 US claimed
EP-1363882-A4 3-(3-AMIDINOPHENYL)-5- ( 1-(1-(-IMINOETHYL)-4-PIPERIDYL AMINO)METHYL]BENZOIC ACID DIHYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME TEIJIN LTD (JP) 2005-11-30 EP claimed
JP-3553083-B2 2004-08-11 JP claimed
JP-2004518683-A 2004-06-24 JP claimed
US-20040053967-A1 3-(3-Amidinophenyl)-5-[({[1-(1-(iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same TEIJIN LIMITED (JP) 2004-03-18 US claimed
EP-1363882-A1 3-(3-AMIDINOPHENYL)-5- ( 1-(1-(-IMINOETHYL)-4-PIPERIDYL AMINO)METHYL]BENZOIC ACID DIHYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME TEIJIN LIMITED (JP) 2003-11-26 EP claimed
WO-2002060873-A1 3-(3-AMIDINOPHENYL)-5-[({[1-(1-(-IMINOETHYL)-4-PIPERIDYL}AMINO)METHYL]BENZOIC ACID DIHYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME TEIJIN LIMITED (JP) 2002-08-08 WO claimed
EP-0852494-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-15 EP claimed
WO-1997009973-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-03-20 WO claimed